#1HYPERFINEⓇ Brain Imaging Within Reach The Swoop® system is driving the future of brain health. Corporate Deck - Nov 2023 Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved.#2Forward-looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the "Company") may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These for ard-looking statements involve significant risks and uncertainties that could cause the act results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under "Risk Factors" therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. 2 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. HYPERFINEⓇ#33 Cost and access limit brain imaging today. Delays in MRI compromise care. Patients shouldn't wait. PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Anytime. Anywhere. The Swoop system brings brain imaging within reach. HYPERFINE,#4The Swoop System is Ready to Transform Brain Imaging and Improve Brain Health 4 Clinically-relevant images with ultra-low-field MRI Safe at multiple sites of care First mover with proprietary technology and Al-powered software Platform technology designed for multiple brain imaging applications PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. 200kg 430 MAX AA0900 HYPERFINE New ultra-low-field brain imaging paradigm - disrupting access and economics and expanding the conventional MRI market FDA-cleared and commercially available in the US with reimbursement under existing CPT codes Global footprint through research institutions and the Bill & Melinda Gates Foundation Unity network HYPERFINEⓇ#5The Swoop System Increases Global MRI Capacity by Enabling Brain Imaging Anywhere 5 Current Paradigm Conventional MRI New Paradigm Point of Care PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Community Access Inpatient Outpatient Pre-hospital Epidemiological Studies ED ICU, Floor Division Clinics Remote / Low Resource Areas Low/Middle Income Countries Courtesy of William T. Kimberly, MD and Kevin Sheth, MD. Swoop system serves multiple sites of care and many applications of significant unmet need globally. Complementary to conventional MRI and existing hospital workflows. HYPERFINE.#6A First for Brain Health Hyperfine, Inc. has reimagined brain imaging with the Swoop system- a powerful brain imaging platform that physicians can use to make clinical decisions when and where it matters most. 6 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved.#7Advancing the Care Experience for All 7 Hyperfine, Inc. is at the forefront of making healthcare more connected, portable, patient-centric, and accessible in less resource-intensive settings. 1 Patients Because empowered patient choices matter. BO PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Clinicians and Care Teams Because timely decisions and personalized care matter. Hospitals Because resources and cost matter. HYPERFINEⓇ#8A New Paradigm in the Economics, Value, and Safety of Brain Imaging 8 00 Low Up-front Capital No Construction or Installation Required Minimal Recurring Costs No Need for Certified Operators Limited Staff Disruption Patient Safety: lonizing Radiation, Heating, Transport Risk Soft Tissue Characterization Conventional MRI PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Swoop System CT Scanner HYPERFINEⓇ#9A Dramatic Improvement in Clinical Workflow The Swoop system streamlines the workflow process to enable timely clinical decisions and reduce risks. 9 Conventional MRI 22 Steps 1.0¹-11.2² Hours High Risk Swoop System PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. 3 Steps 0.5¹ 4.52 Hours Low Risk 1. Mazurek, M.H., Cahn, B.A., Yuen, M.M. et al. Portable, bedside, low-field magnetic resonance imaging for evaluation of intracerebral hemorrhage. Nat Commun 12, 5119 (2021). https://doi.org/10.1038/s41467-021-25441-6 2. Kuoy et al. Point-of-Care Brain MRI: Preliminary Results from a Single-Center Retrospective Study. Radiology 2022 https://doi.org/10.1148/radiol.211721 55% Time Reduction² HYPERFINEⓇ#10Immediate Clinical Applications, Blueprint for Continued Growth Current Commercial and Clinical Applications Clinical Research and R&D for Future Applications 10 m Critical Care Pediatrics Stroke Alzheimer's CONFIDENTIAL - PROPERTY OF HYPERFINE, INC. ©2023, All rights reserved. Future Opportunities Remote Care Delivery Global Expansion New Use Cases The Swoop system expands the fast growing (6% annual CAGR) $35 billion global imaging market. HYPERFINE.#11Deep Foundation to Drive Long-term Success 0000 Clinical Proof HYPERFINEⓇ Regulatory Excellence 11 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. X Ecosystem of Support Rapid Innovation HYPERFINEⓇ#12Rapid innovation: Proven Record of Releasing New Technology to the Market a F 12 Al-powered Imaging 2020 SONO 2021 010110 101100 Hardware (1.7) and software (8.1): Brain imaging for all ages. 010110 101100 Hardware (1.6) and software (8.0): The world's first bedside MRI system for brain imaging of patients ages 2 and up. 2022 Hardware (1.8) and software (8.2): Additional automatic alignment and motion correction features. PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. 010110 101100 2023 010110 101100 Software (8.3): Elevated diagnostic value: advanced image reconstruction leveraging deep learning for T1, T2, and FLAIR sequences. 010110 101100 Software (8.7): Al denoising in DWI sequence. Software (8.6): Significant DWI improvements, Advanced motion compensation. Software (8.5): DWI image quality improvement, improved intensity uniformity, faster image acquisition. Hardware (1.9): Updates to hardware components and minimum patient weight limit. Software (8.4): Fast T2: 50% faster option to the existing higher-quality T2 sequence. T1 (Standard): better intraparenchymal visibility, improved noise cancellation. Strong IP portfolio with over 150 patents worldwide. HYPERFINEⓇ#13Regulatory Excellence: Success in Multiple Geographies USA 2020 The Swoop system is cleared for brain imaging of patients of all ages. Nine FDA clearances since 2020. Most recently cleared under K232760. *Not yet commercialized 13 European Union* 2023 The Swoop system has CE certification for the European Union. ● ● KM United Kingdom* 2022 The Swoop system has UKCA certification for the United Kingdom. PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Canada 2021 The Swoop system is approved for commercial sale in Canada. (Health Canada License 107054) NZ ZN Australia 2022 Broad tion for imaging of the brain. Nine FDA clearances for the Swoop system in the last 36 months. CE certification achieved under latest MDR regulations. The Swoop system is approved for commercial sale in Australia. (TGA ARTG Identifier 384545) NZ ZN New Zealand 2022 The Swoop system notified to WAND database and available for commercial sale in New Zealand. HYPERFINE.#14Clinical Proof: Twenty-five Peer-Reviewed Publications to Date and Significant Investment in Studies in New Clinical Use Cases American Journal of Neuroradiology, April 2022 Implementation of a Low-Field Portable MRI Scanner in a Resource- Constrained Environment: Our Experience in Malawi Acquired >260 brain scans; concluded use may lead to faster diagnosis and expedited treatment, including in comatose patients in the E.D. and bed-bound patients with sudden onset neurologic deficits Science Advances, April 2022 Portable, Low-Field MRI Enables Highly Accessible and Dynamic Bedside Evaluation of Ischemic Stroke Imaged 50 confirmed acute ischemic stroke patients; accurately detected infarcts in 45 (90%) ; captured lesions as small as 4mm Nature Communications, August 2021 Portable, Bedside, Low-Field Magnetic Resonance Imaging for Evaluation of Intracerebral Hemorrhage Imaged >140 patients and correctly identified ICH in over 80% of confirmed cases 14 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Key Observational Studies Pursuing Multiple Clinical Applications ACTION PMR (Stroke) • HOPE PMR (Hydrocephalus) • SAFE MRI (ECMO) ● Presented initial findings at Asia-Pacific Extracorporeal Life Support Organization (APELSO) Meeting in November 2023 HYPERFINEⓇ#15Ecosystem of Support: Scalable, Low-cost, Connected, and Customer-centric 15 Connectivity to integrate across radiology information systems Over-the-air software upgrades to enable rapid enhancements PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Cloud for image and data viewing M (H) Cybersecurity: HITRUST and SOC2 type1 certifications Remote technical support and service to maximize customer uptime HYPERFINEⓇ#16Strong Financial Position to Fuel Future Growth Revenue $0.30 16 2020 $1.50 *2023 revenue guidance: $11M to $13M $6.80 2021 2022 Revenue in Millions $11-$13* 2023 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Growth Drivers: • Swoop system sales: Maturing ● commercial team and broadening use cases across critical care and pediatrics. • Pricing ● Service revenue ● HYPERFINEⓇ#17Strong Financial Position to Fuel Future Growth Gross Margin 2021 17 -80% *2023 gross margin guidance: 44% to 46%. 13% 2022 Gross Margin % 44%-46%* 2023 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Growth Drivers: • Achieving significant leverage through ● commercialization, cost control, and Swoop system pricing. HYPERFINEⓇ#18Strong Financial Position to Fuel Future Growth Cash Burn $71 18 2022 *2023 cash burn guidance: $41to $44 million. $41-$44* Cash Burn In Millions 2023 Reducing cash burn with runway through 2025 while focusing spend on three strategic pillars: Innovation: Hardware and software (Al) updates. • Clinical evidence: Expanding clinical applications. ● PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. ● • Commercialization: Building the pipeline for US Swoop system sales. Cash and Cash Equivalents of $85.4M as of September 30, 2023 HYPERFINE.#19Hyperfine, Inc. Leadership Team Brings a Proven Track Record of Success 19 Maria Sainz President & Chief Executive Officer PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Brett Hale Chief Administrative Officer and Chief Financial Officer Tom Teisseyre Chief Operating Officer HYPERFINEⓇ#20The Hyperfine, Inc. Opportunity 20 BO First FDA-cleared portable ultra-low-field MR brain imaging system expanding a multi-billion- dollar market Commercial stage company expanding the brain imaging market to solve for substantial unmet provider and patient need Prolific engine of fast innovation and clinical evidence based on strong proprietary technology PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. B 40 Platform technology with significant greenfield opportunities in neurocritical care, hydrocephalus, stroke, and Alzheimer's Early track record of rapid topline and gross margin growth with healthy cash runway Highly experienced executive team with deep industry expertise HYPERFINEⓇ#21HYPERFINE. Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved.#22Clinical Publications Assessment of Brain Injury Using Portable, Low-Field Magnetic Resonance Imaging at the Bedside of Critically Ill Patients. Sheth KN, et al. JAMA Neurol. 2020. doi:10.1001/jamaneurol.2020.3263 Portable Magnetic Resonance Imaging for ICU Patients. Crit Care. Turpin J, et al. Explor. 2020;2:e0306-e0306. doi:10.1097/CCE.0000000000000306 Accessible pediatric neuroimaging using a low field strength MRI scanner. Deoni SCL, et al. Neurolmage. 2021 238:118273. doi:10.1016/j.neuroimage.2021.118273 Portable, bedside, low-field magnetic resonance imaging for evaluation of intracerebral hemorrhage. Mazurek MH, et al. Nat Commun. 2021;12:5119. doi:10.1038/s41467-021-25441-6 Methodology for Low-Field, Portable Magnetic Resonance Neuroimaging at the side. Prabhat AM, et al. Frontiers in Neurology. 2021;12:2191. doi:10.3389/fneur.2021.760321 Simulated diagnostic performance of low-field MRI: Harnessing open-access datasets to evaluate novel devices. Arnold TC, et al. Magnetic Resonance Imaging. 2022:87:67-76. doi:10.1016/j.mri.2021.12.007 Sensitivity of Portable Low-Field Magnetic Resonance Imaging for Multiple Sclerosis Lesions. Arnold TC, et al. Neurolmage: Clinical. 2022:103101. doi:10.1016/j.nicl.2022.103101 Bedside monitoring of hypoxic ischemic brain injury using low-field, portable brain magnetic resonance imaging after cardiac arrest. Beekman R, et al. Resuscitation. 2022;176:150-158. doi:10.1016/j.resuscitation.2022.05.002 Assessing the SAfety and FEasibility of bedside portable low-field brain Magnetic Resonance Imaging in patients on ECMO (SAFE-MRI ECMO study): study protocol and first case series experience. Cho S-M, et al. Critical Care. 2022;26:119. doi:10.1186/s13054-022-03990-6 Neuroimaging and verbal memory assessment in healthy aging adults using a portable low-field MRI scanner and a web-based platform: results from a proof-of-concept population-based cross-section study. Deoni SCL, et al. Brain Struct Funct. 2023;228(2)L493-509. doi: 10.1007/s00429-022-02595-7 Development of a mobile low-field MRI scanner. Deoni SCL, et al. Sci Rep. 2022;12:5690. doi:10.1038/s41598- 022-09760-2 Simultaneous high-resolution T2-weighted imaging and quantitative T2 mapping at low magnetic field strengths using a multiple TE and multi-orientation acquisition approach. Deoni SCL, et al. Magn Reson Med. 2022;88(3):1273-1281. doi:10.1002/mrm.29273 22 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Quantitative Brain Morphometry of Portable Low-Field-Strength MRI Using Super-Resolution Machine Learning. Iglesias JE, et al. Radiology. 2023;306(3):e220522. doi:10.1148/radiol.220522 Point-of-Care Brain MRI: Preliminary Results from a Single-Center Retrospective Study. Kuoy E, et al. Radiology. 2022;305(3):666-671. doi:10.1148/radiol.211721 In vivo T1 mapping of neonatal brain tissue at 64 mT. Padormo, et al. Magn Reson Med. 2023;89(3):1016- 1025. doi:10.1002/mrm.29509 Bedside detection of intracranial midline shift using portable magnetic resonance imaging. Sheth KN, et al. Scil Rep. 2022;12(1):67. Published 2022 Jan 7. doi:10.1038/s41598-021-03892-7 Feasibility of and experience using a portable MRI scanner in the neonatal intensive care unit. Sien ME, et al. Arch Dis Child Fetal Neonatal Ed. 2023;108(1):45-50. doi:10.1136/archdischild-2022-324200 Safety of Bedside Portable Low-Field Brain MRI in ECMO Patients Supported on Intra-Aortic Balloon Pump. Wilcox C, et al. Diagnostics (Basel). 2022;12(11):2871. Published 2022 Nov 19. doi:10.3390/diagnostics 12112871 Portable, low-field magnetic resonance imaging enables highly accessible and dynamic bedside evaluation of ischemic stroke. Yuen MM, et al. Sci Adv. 2022;8(16):eabm3952. doi:10.1126/sciadv.abm3952 Dual-domain self-supervised learning for accelerated non-Cartesian MRI reconstruction. Zhou B, et al. Med Image Anal. 2022;81:102538. doi:10.1016/j.media.2022.102538 Feasibility of bedside portable MRI in neonates and children during ECLS. Sabir H, et al. Crit Care. 2023;27(1):134. Published 2023 Apr 4. doi:10.1186/s13054-023-04416-7 In vivo quantitative MRI: T1 and T2 measurements of the human brain at 0.064 T. Jordanova KV, et al. MAGMA. 2023;10.1007/s10334-023-01095-x. doi:10.1007/s10334-023-01095-x 3 | LBL-002607 v0 Identification of White Matter Hyperintensities in Routine Emergency Department Visits Using Portable Bedside Magnetic Resonance Imaging, de Havenon A, et al. J Am Heart Assoc. 2023;12(11):e029242. doi:10.1161/JAHA.122.029242 Image quality assessment of advanced reconstruction algorithm for point-of-care MRI scanner. Krupinski EA, et al. J Med Imaging (Bellingham). 2023;10(Suppl 1):S11913. doi:10.1117/1JMI.10.S1.S11913 Intraoperative use of Ultra-Low-field, Portable MRI- First report, Altaf A, et al. Surg Neurol Int. 2023;14:212. Published 2023 Jun 23. doi:10.25259/SNI_124_2023 Portable MRI to assess optic chiasm decompression after endoscopic endonasal resection of sellar and suprasellar lesions. Hong CS, et al. J Neurosurg. 2023;1-7. doi:10.3171/2023.5JNS23174 HYPERFINE.